Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited Pierre Fabre to submit evidence for the clinical and cost-effectiveness of encorafenib with binimetinib (Enco + Bini) versus dabrafenib with trametinib (Dab + Tram) as a first-lin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoecon Open
Main Authors: Houten, Rachel, Greenhalgh, Janette, Mahon, James, Nevitt, Sarah, Beale, Sophie, Boland, Angela, Lambe, Tosin, Dundar, Yenal, Kotas, Eleanor, McEntee, Joanne
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7895893/
https://ncbi.nlm.nih.gov/pubmed/32291725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00206-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados